CAMBRIDGE, Mass.--(BUSINESS WIRE)--After a thorough head-to-head evaluation against various competing solutions, the Center for Cancer Computational Biology (CCCB) at the Dana-Farber Cancer Institute has selected CLC bio’s enterprise platform for next generation sequence analysis.
